The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.
The blood screening market involves the testing of donated blood and plasma for infectious diseases, genetic disorders, and other health markers to ensure safety and accuracy before transfusion or further medical use. This market is driven by the growing need for early diagnosis, increasing prevalence of chronic and infectious diseases, and the expansion of blood donation and transfusion services globally. Technological advancements, such as nucleic acid testing (NAT), immunoassays, and automation in diagnostic laboratories, have significantly enhanced the efficiency and reliability of blood screening processes. As healthcare systems focus more on preventive care and patient safety, the Blood Screening Market continues to gain momentum. Despite some challenges such as high costs and limited infrastructure in low-resource regions, the ongoing demand for high-quality diagnostics sustains the long-term growth of the Blood Screening Market.
Continue reading for more details:
https://www.fortunebusinessinsights.com/blood-screening-market-102552
Market Segmentation
List Of Key Companies Profiled: